EPHX2 and kidney disorder: A possible limitation of sEH inhibition that emerges in the context of kidney diseases is that the concomitant potentiation of other epoxyfatty acids with sEH inhibition, especially those derived from omega-3, may hamper the beneficial renal impact of EETs.